Warburg puts up $300M to launch a buyout-hungry drug firm

Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets. Headquartered in New York, Vertice is getting off the ground with plans to acquire branded and generic products, piecing together a scalable business in the process. Former Endo Pharmaceuticals ($ENDP) Chief Operating Officer Don DeGolyer is on board as CEO, joined by Auxilium Pharmaceuticals veteran Andrew Saik in the chief financial officer role. The company's first move was acquiring generics manufacturer VistaPharm for an undisclosed sum, establishing a production base for its future endeavors. Release